Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis

Journal of Gastroenterology

Volumn 48, Issue 4, 2013, Pages 491-503

  Tamaki, Yosui ^a   Nakade, Yukiomi ^b   Yamauchi, Taeko ^b   Makino, Yuichi ^a   Yokohama, Shiro ^a   Okada, Mitsuyoshi ^a   Aso, Kazunobu ^a   Kanamori, Hiroyuki ^b   Ohashi, Tomohiko ^b   Sato, Ken ^b   Nakao, Haruhisa ^b   Haneda, Masakazu ^a   Yoneda, Masashi ^b  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II type 1 receptor blocker; Hepatic carcinogenesis; Non alcoholic steatohepatitis

Indexed keywords

AMINO ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; TELMISARTAN; VASCULOTROPIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; HIF1A PROTEIN, RAT; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; HISTOPATHOLOGY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; VITAMIN DEFICIENCY; ANIMAL; BIOSYNTHESIS; CELL TRANSFORMATION; DIET; DRUG EFFECT; DRUG SCREENING; FATTY LIVER; GENE EXPRESSION REGULATION; GENETICS; LIVER; LIVER TUMOR; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION; WISTAR RAT;

AMINO ACIDS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTICARCINOGENIC AGENTS; BENZIMIDAZOLES; BENZOATES; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; CHOLINE DEFICIENCY; DIET; DRUG EVALUATION, PRECLINICAL; FATTY LIVER; GENE EXPRESSION REGULATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, WISTAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84886514953     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0651-7     Document Type: Article

References (58)

1. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005;42: 44-52.
2. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28: 339-50.
3. Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Hepatol. 2002;37: 154-60.
4. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135: 111-21.
5. Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst. 2000;92: 1096-9.
6. Pieruzzi F, Abassi ZA, Keiser HR. Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure. Circulation. 1995;92: 3105-12.
7. Kamezaki F, Tasaki H, Yamashita K, Shibata K, Hirakawa N, Tsutsui M, et al. Angiotensin receptor blocker improves coronary flow velocity reserve in hypertensive patients: comparison with calcium channel blocker. Hypertens Res. 2007;30: 699-706.
8. Stock P, Liefeldt L, Paul M, Ganten D. Local renin-angiotensin systems in cardiovascular tissues: localization and functional role. Cardiology. 1995;86(Suppl 1): 2-8.
9. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001;34: 745-50.
10. Bataller R, Sancho-Bru P, Gines P, Lora JM, Al-Garawi A, Sole M, et al. Activated human hepatic stellate cells express the renin- angiotensin system and synthesize angiotensin II. Gastroenterology. 2003;125: 117-25.
11. Helmy A, Jalan R, Newby DE, Hayes PC, Webb DJ. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology. 2000;118: 565-72.
12. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40: 1222-5.
13. Yokohama S, Tokusashi Y, Nakamura K, Tamaki Y, Okamoto S, Okada M, et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol. 2006;12: 322-6.
14. Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, Yoshioka A, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology. 2007;45: 1375-81.
15. Jin H, Yamamoto N, Uchida K, Terai S, Sakaida I. Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun. 2007;364: 801-7.
16. Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, et al. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut. 2005;54: 1768-75.
17. Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2005;65: 3691-9.
18. Yoshiji H, Kuriyama S, Noguchi R, Ikenaka Y, Kitade M, Kaji K, et al. Angiotensin-II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development. Hepatol Res. 2006;36: 124-9.
19. Ghoshal AK, Farber E. The induction of liver cancer by dietary deficiency of choline and methionine without added carcinogens. Carcinogenesis. 1984;5: 1367-70.
20. Squire RA, Levitt MH. Report of a workshop on classification of specific hepatocellular lesions in rats. Cancer Res. 1975;35: 3214-23.
21. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21: 3-16.
22. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51: 1972-8.
23. Morgan TR, Mandayam S, Jamal MM, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology. 2004;127:S87-96.
24. Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009;16: 453-63.
25. Sakaida I, Matsumura Y, Kubota M, Kayano K, Takenaka K, Okita K. The prolyl 4-hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline-deficient L-amino acid-defined diet. Hepatology. 1996;23: 755-63.
26. Ghoshal AK, Ahluwalia M, Farber E. The rapid induction of liver cell death in rats fed a choline-deficient methionine-low diet. Am J Pathol. 1983;113: 309-14.
27. Yao ZM, Vance DE. The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. J Biol Chem. 1988;263: 2998-3004.
28. Nakae D, Yoshiji H, Maruyama H, Kinugasa T, Denda A, Konishi Y. Production of both 8-hydroxydeoxyguanosine in liver DNA and gamma- glutamyltransferase-positive hepatocellular lesions in rats given a choline-deficient, L-amino acid-defined diet. Jpn J Cancer Res. 1990;81: 1081-4.
29. Nakae D. Endogenous liver carcinogenesis in the rat. Pathol Int. 1999;49: 1028-42.
30. Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, et al. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1. Gastroenterology. 2003;125: 556-71.
31. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol. 2002;37: 56-62.
32. Fox ES, Brower JS, Bellezzo JM, Leingang KA. N-acetylcysteine and alpha-tocopherol reverse the inflammatory response in activated rat Kupffer cells. J Immunol. 1997;158: 5418-23.
33. Goossens V, Grooten J, De Vos K, Fiers W. Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci USA. 1995;92: 8115-9.
34. Bataller R, Gabele E, Parsons CJ, Morris T, Yang L, Schoonhoven R, et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology. 2005;41: 1046-55.
35. Grotendorst GR. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 1997;8: 171-9.
36. Paradis V, Dargere D, Bonvoust F, Vidaud M, Segarini P, Bedossa P. Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab Invest. 2002;82: 767-74.
37. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma- epidemiological trends and risk factors. Dig Dis. 2009;27: 80-92.
38. Sakaida I, Hironaka K, Uchida K, Suzuki C, Kayano K, Okita K. Fibrosis accelerates the development of enzyme-altered lesions in the rat liver. Hepatology. 1998;28: 1247-52.
39. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis. 2000;21: 505-15.
40. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 1999;284: 808-12.
41. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69(Suppl 3): 4-10.
42. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, et al. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology. 2001;39: 1517-24.
43. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3: 721-32.
44. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000;19: 4298-309.
45. Onori P, Morini S, Franchitto A, Sferra R, Alvaro D, Gaudio E. Hepatic microvascular features in experimental cirrhosis: a structural and morphometrical study in CCl4-treated rats. J Hepatol. 2000;33: 555-63.
46. Wang YQ, Luk JM, Ikeda K, Man K, Chu AC, Kaneda K, et al. Regulatory role of vHL/HIF-1alpha in hypoxia-induced VEGF production in hepatic stellate cells. Biochem Biophys Res Commun. 2004;317: 358-62.
47. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today. 2007;12: 853-9.
48. Nakamura K, Zen Y, Sato Y, Kozaka K, Matsui O, Harada K, et al. Vascular endothelial growth factor, its receptor Flk-1, and hypoxia inducible factor-1alpha are involved in malignant transformation in dysplastic nodules of the liver. Hum Pathol. 2007;38: 1532-46.
49. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA. 1997;94: 8104-9.
50. Fujita K, Yoneda M, Wada K, Mawatari H, Takahashi H, Kirikoshi H, et al. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci. 2007;52: 3455-64.
51. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109: 2054-7.
52. Sugimoto K, Kazdova L, Qi NR, Hyakukoku M, Kren V, Simakova M, et al. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptorgamma dependent pathway. J Hypertens. 2008;26: 1209-15.
53. Moreno M, Ramalho LN, Sancho-Bru P, Ruiz-Ortega M, Ramalho F, Abraldes JG, et al. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol. 2009;296:G147-56.
54. Bartoli M, Al-Shabrawey M, Labazi M, Behzadian MA, Istanboli M, El-Remessy AB, et al. HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2009;50: 4934-40.
55. Xu K, Ding Q, Fang Z, Zheng J, Gao P, Lu Y, et al. Silencing of HIF-1alpha suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis. Cancer Gene Ther. 2010;17: 212-22.
56. Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, Shirai Y, et al. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. Am J Physiol Gastrointest Liver Physiol. 2011;300:G1094-104.
57. Kudo H, Yata Y, Takahara T, Kawai K, Nakayama Y, Kanayama M, et al. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int. 2009;29: 988-96.
58. Sanchez-Lopez E, Lopez AF, Esteban V, Yague S, Egido J, Ruiz- Ortega M, et al. Angiotensin II regulates vascular endothelial growth factor via hypoxia-inducible factor-1alpha induction and redox mechanisms in the kidney. Antioxid Redox Signal. 2005;7: 1275-84.